As it awaits a decision from the FDA on its PMA, Pulmonx Corp. touted positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr endobronchial valve for severe emphysema, including statistically significant reduction in the rate of respiratory failure in patients receiving the device. If approved, the therapy would offer a new choice for patients with limited options and who experience a poor quality of life.